# Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR

> **NCT04773392** · PHASE4 · TERMINATED · sponsor: **University of Southern California** · enrollment: 20 (actual)

## Conditions studied

- Kidney Transplantation
- Kidney Transplant Rejection

## Interventions

- **DRUG:** Twice-daily Tacrolimus
- **DRUG:** Once-daily envarsus XR
- **DRUG:** Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG)
- **DRUG:** Methylprednisolone, prednisone
- **DRUG:** Mycophenolate mofetil (MMF) or Mycophenolic acid (MPA)
- **DRUG:** Azathioprine

## Key facts

- **NCT ID:** NCT04773392
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-23
- **Primary completion:** 2024-02-23
- **Final completion:** 2024-02-23
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Research contract expired
- **Last updated:** 2025-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04773392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04773392, "Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04773392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*